Forma Therapeutics penned an $815 million oncology drug discovery alliance with BI. BMS and Amgen spent over $1 billion each to purchase Inhibitex and Micromet, respectively. And AngioDynamics acquired Navilyst Medical for $367 million. Biopharma and device financing both increased in January from the previous month.
Exhibit 1
Top Alliances In January 2012
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
